2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Singularity Future Technology Ltd. sold common stock and pre-funded warrants in two registered direct offerings, dated August 18 and August 20, 2026, for gross proceeds of about $1.8 million and $5.0 million before fees and expenses. The company will use the proceeds for working capital and, in the second offering, its planned data center business, and the new shares and warrants add to the share count shareholders own.
First offering, closed August 19, 2026: 340,000 common shares at $3.00 each plus pre-funded warrants for 260,000 shares, for about $1.8 million gross.
Second offering, closed August 21, 2026: 451,250 common shares at $3.20 each plus pre-funded warrants for up to 1,111,250 shares, for about $5.0 million gross.
Placement agent Univest Securities LLC receives a fee of 7% of gross proceeds, and the company agreed not to issue more shares or file new registration statements for 30 days after the closings.
The Purchaser's right to buy up to an additional 100% of its first-offering shares, which ran through September 18, 2026, was terminated.
Ensysce Biosciences said its first tranche of a Series C Preferred Stock financing, totaling roughly $43 million, closed on August 7, 2026, raising more than $21 million in gross proceeds. The company believes this restores compliance with Nasdaq's minimum stockholders' equity requirement and that it qualifies for a second 180-day grace period to regain compliance with the $1.00 bid price rule.
First tranche closed August 7, 2026, raising more than $21 million gross; total financing is about $43 million for 120,260 Series C Preferred shares
Second tranche depends on a clinical trial milestone that has not yet occurred
Company believes stockholders' equity is at least $2.5 million, meeting the Nasdaq Rule 5550(b)(1) requirement, pending Nasdaq confirmation
Second 180-day bid price grace period was requested from Nasdaq on August 24, 2026; Nasdaq response is pending
Rackspace Technology said its President, Public Cloud, Dharmendra Kumar Sinha, is expected to leave the role on or about September 14, 2026. The company said the departure is not due to any disagreement over its operations, policies or practices, and a separation agreement is being negotiated.
Dharmendra Kumar Sinha expected to depart as President, Public Cloud, effective on or about September 14, 2026
Departure is not the result of any disagreement with the company on operations, policies or practices
Separation agreement under negotiation, expected to follow his employment agreement terms and include customary releases and restrictive covenants
Separation agreement expected to be filed as an exhibit to the Form 10-Q for the period ending September 30, 2026
Abacus furnished a shareholder letter dated August 24, 2026, from Chief Investment Officer Elena Plesco, covering interest rates, a valuation methodology change, and first-half 2026 results. The letter says Q2 2026 revenue grew 30% year over year to $73.0 million and adjusted net income reached $27.1 million, above the high end of company guidance. The company also moved to a Historical Return Method for valuing policies starting in Q2 2026, which shareholders may want to weigh alongside the reported results.
Q2 2026 revenue grew 30% year over year to $73.0 million, led by Life Solutions, which grew 38.3%.
Adjusted net income was $27.1 million, above the high end of company guidance; adjusted EBITDA grew 27% to $39.9 million.
Starting in Q2 2026, policies are valued under an updated Historical Return Method that applies observed returns to cost basis instead of discounting modeled cash flows.
Capital deployed was close to $200 million in Q2 2026 and $362 million year to date; adjusted figures are non-GAAP measures.
Jupiter Neurosciences sold 307,692 shares at $6.50 each in a registered direct offering that closed August 24, 2026, for gross proceeds of about $2.0 million before fees and expenses. The company believes the sale brings its stockholders' equity above the $2.5 million Nasdaq continued-listing requirement, but it is still waiting for Nasdaq's formal confirmation, and its shares may face delisting if compliance is not shown at its next periodic report.
Shares issued: 307,692 common shares at $6.50 each, under an agreement dated August 21, 2026
Gross proceeds: approximately $2.0 million before placement agent fees and offering expenses, closed August 24, 2026
Nasdaq stockholders' equity requirement: $2.5 million; company awaiting formal determination of compliance
Delisting risk remains if compliance is not evidenced at the next periodic report
Hormel Foods appointed Ash Bhumbla as Executive Vice President and Chief Financial Officer, effective September 8, 2026, ending Paul R. Kuehneman's service as interim CFO on that date. Mr. Bhumbla most recently served as Senior Vice President and CFO, Chicken segment, at Tyson Foods, and the filing sets out a base salary of $700,000 and sign-on awards for shareholders to weigh in the company's disclosed pay package.
Ash Bhumbla becomes Executive Vice President and Chief Financial Officer effective September 8, 2026
Paul R. Kuehneman's interim CFO role ends; he remains Vice President and Controller and Principal Accounting Officer
Bhumbla's offer includes a $700,000 base salary and an annual long-term incentive target of $2.1 million
Sign-on package includes a $700,000 cash award and restricted stock units with a $1.2 million grant date value
Backblaze issued $201.25 million of 0.00% convertible senior notes maturing August 15, 2031, including the full $26.25 million option exercised by the initial purchasers. The notes can convert into cash, Class A common stock, or both at the company's election, at about $21.94 per share, a 30% premium to the $16.88 closing price on August 19, 2026. The new debt could dilute existing shareholders if converted, though the company also bought capped call transactions, at a cost of about $17.5 million, that are intended to reduce that dilution.
Notes totaling $201.25 million were issued August 24, 2026, including the $26.25 million option exercised in full.
Initial conversion price is about $21.94 per share, a 30% premium to the $16.88 closing price on August 19, 2026.
Capped call transactions cost about $17.5 million, with a cap price of $33.76 per share.
The revolving credit facility rose from $20 million to $50 million and its maturity was extended from June 4, 2028 to April 30, 2030.
On August 24, 2026, Charter Communications Operating and its co-issuer completed the final settlement of their exchange offers for senior secured notes, issuing additional 2038 and 2041 notes in exchange for older notes. The exchanges swap existing debt for new 7.087% and 7.337% senior secured notes, so the filing shows a refinancing of existing obligations rather than new borrowing in cash.
Final Settlement Date was August 24, 2026, after the offers expired at 5:00 p.m. New York City time on August 20, 2026.
Issued $55,928,000 in additional 7.087% Senior Secured Notes due 2038 in exchange for $84,390,000 of Pool 1 notes.
Issued $35,750,000 in additional 7.337% Senior Secured Notes due 2041 in exchange for $60,634,000 of Pool 2 notes.
New notes are senior secured and mature in 2038 and 2041, with interest payable each March 1 and September 1, starting March 1, 2027.
Hub Group received a Nasdaq notice on August 20, 2026 that it is not in compliance with Listing Rule 5250(c)(1) because it has not timely filed its quarterly report for the quarter ended June 30, 2026. The notice has no immediate effect on the listing or trading of the Class A common stock, but the company must submit an updated plan to regain compliance by August 27, 2026, and any further exception is capped at September 14, 2026.
Nasdaq notice dated August 20, 2026 cites late Form 10-Q for the quarter ended June 30, 2026 under Listing Rule 5250(c)(1)
Company must submit an updated compliance plan to Nasdaq by August 27, 2026
Delinquent 2025 Form 10-K and Q1 2026 Form 10-Q have an exception deadline of September 14, 2026
Notice has no immediate effect on listing or trading on the Nasdaq Global Select Market
Pantages Capital Acquisition Corporation received a Nasdaq notice on August 21, 2026, stating that its market value of listed securities has been below the $50 million minimum for 30 consecutive business days. Nasdaq said the notice is only a deficiency notification with no current effect on listing or trading, but the company has until February 17, 2027 to regain compliance or face a possible delisting notice.
Nasdaq notice dated August 21, 2026 cites the $50 million minimum market value of listed securities for continued listing on the Nasdaq Global Market.
The company also does not meet Nasdaq Listing Rule 5450(b)(3)(A), according to the notice.
Compliance Period runs 180 calendar days to February 17, 2027; regaining compliance requires at least $50 million for 10 consecutive business days.
The company says it is monitoring its market value and evaluating options, but gives no assurance it will regain or maintain compliance.
On August 18, 2026, Air Industries Group signed a Twelfth Amendment to its Loan and Security Agreement with Webster Bank, extending the maturity of its revolving credit and term loans to November 30, 2026. Concurrently, the holders of its subordinated notes, Michael Taglich and Robert Taglich, agreed to extend those notes' maturity to December 1, 2026. The filing does not state loan amounts or other terms, so the change mainly moves the dates by which the company must repay this debt.
Twelfth Amendment to Loan and Security Agreement with Webster Bank dated August 18, 2026
Revolving credit and term loan maturity extended to November 30, 2026
Subordinated notes held by Michael Taglich and Robert Taglich extended to December 1, 2026
Filing dated August 24, 2026 and signed by Acting Chief Executive Officer Scott Glassman; loan amounts not disclosed in the filing
Aveanna Healthcare Holdings disclosed an underwriting agreement dated August 20, 2026, for a secondary offering of 15,000,000 shares of common stock by certain selling stockholders, including affiliates of J.H. Whitney Equity Partners VII, LLC, at $11.75 per share. The offering closed on August 24, 2026, and the company received no proceeds, so the sale adds shares held by the public without new capital for the company.
Selling stockholders offered 15,000,000 shares at a public offering price of $11.75 per share, with RBC Capital Markets, LLC as underwriter.
The underwriter received a 30-day option to buy up to an additional 2,250,000 shares from the selling stockholders.
The secondary offering closed on August 24, 2026; the company did not issue or sell any shares and received no proceeds.
Tyson Foods completed a public offering of $1 billion in senior unsecured notes on August 24, 2026, split evenly between $500 million of 5.100% notes due 2031 and $500 million of 5.600% notes due 2037. The filing describes the terms and covenants of the notes, which add to the company's debt obligations and carry fixed interest payments through maturity.
$500 million of 5.100% Senior Notes mature August 24, 2031; interest paid semiannually from February 24, 2027
$500 million of 5.600% Senior Notes mature January 24, 2037; interest paid semiannually from January 24, 2027
Notes are general senior unsecured obligations, ranking equally with the company's other senior unsecured debt
Indenture limits secured debt, sale and lease-back transactions, and mergers or asset transfers, subject to exceptions
On August 24, 2026, Valvoline closed a $600 million offering of 6.125% senior notes maturing August 15, 2034, and plans to use the proceeds mainly to repay its senior secured term loan A in full and partly repay term loan B. The same day, it amended its credit agreement to raise the revolving credit facility from $475 million to $600 million, extend its maturity five years from August 24, 2026, and raise the maximum consolidated net leverage covenant from 4.50:1.00 to 5.00:1.00, stepping down later. The filing shows more borrowing capacity and covenant room for Valvoline, alongside new long-term debt.
$600 million of 6.125% senior notes due August 15, 2034, closed August 24, 2026; trustee is U.S. Bank Trust Company, National Association
Net proceeds intended to repay term loan A in full, partly repay term loan B, and pay fees and expenses
Revolving credit facility increased from $475 million to $600 million, with pricing reduced and maturity extended
Maximum consolidated net leverage covenant raised from 4.50:1.00 to 5.00:1.00, stepping down to 4.75:1.00 and 4.50:1.00 in years three and four
CPS Technologies entered into a lease dated August 19, 2026, for about 80,000 square feet at 523 Pleasant Street in Attleboro, Massachusetts. The company plans to move its corporate offices, manufacturing and product development there from Norton, Massachusetts during 2027, with base rent starting December 1, 2027.
Lease term is twelve years and ten months from August 19, 2026, with a construction period through May 31, 2027 and six months of base-rent-free time through November 30, 2027.
Base rent is $85,000 per month for the first six months, then about $1.05 million for the following lease year, rising 3% annually thereafter.
The landlord, VMD Industrial II, LLC, will contribute up to $3.2 million toward qualifying improvements after the company spends at least $1.6 million, and the company must post a $510,000 security deposit.
Oruka Therapeutics said Todd Edwards began work as its Chief Commercial Officer on August 24, 2026, under an offer letter dated July 22, 2026. Edwards previously held commercial roles at Arcutis Biotherapeutics and Incyte, and his pay package includes a $525,000 base salary, a 40% target bonus and equity grants. The appointment fills a senior commercial role, and the filing discloses the severance terms that apply if his employment ends.
Base salary of $525,000 with a discretionary bonus targeted at 40% of base salary
Stock option for 20,000 shares and RSUs for 100,000 shares, with 25% vesting on August 24, 2027
Signing bonus of $200,000, payable within 30 days of starting employment
Severance of 12 months' base salary without a change in control; 1.0 times base salary plus target bonus if termination occurs within three months before or 12 months after a change in control
On August 21, 2026, Twin Vee PowerCats' Compensation Committee revised CEO and President Joseph Visconti's base salary to $250,000. Visconti is also eligible for a $150,000 bonus if the Agreement and Plan of Merger with USFM Corporation, dated July 12, 2026, closes, payable within ten days of closing. The filing does not state the prior salary, so the size of the change is not clear, and shareholders should note that the bonus depends on the merger completing.
Base salary revised to $250,000 by the Compensation Committee on August 21, 2026.
Bonus of $150,000 is eligible upon successful completion and closing of the USFM merger.
Bonus payable within ten days of the merger closing, if the merger closes.
Merger Agreement with USFM Corporation is dated July 12, 2026.
Presidio Property Trust completed a five-year lease extension with Johns Hopkins University, its largest tenant, for the Bloomberg School of Public Health at its Baltimore property. The filing does not disclose rent or revenue figures, so the financial effect on shareholders cannot be gauged from this document.
Lease extension completed on August 20, 2026, extending the term to December 31, 2031
Johns Hopkins University occupies all 31,752 square feet of the Baltimore property
Chief Investment Officer Gary Katz said the company is pleased the property fits the tenant's long-term needs
Press release furnished under Item 7.01 and not deemed filed under Section 18 of the Exchange Act
Grand Canyon Education said its Chief Financial Officer, Daniel E. Bachus, was placed on paid administrative leave effective August 21, 2026, in connection with an ongoing governmental investigation involving a non-employee third party's trades in Company stock. The Company said the leave is not related to its financial statements or accounting, and that it is not a focus of the investigation. The board named Lori Browning, its Chief Accounting Officer, as interim CFO and interim principal financial officer.
Daniel E. Bachus, CFO, placed on paid administrative leave effective August 21, 2026
Lori Browning, SVP & Controller – Chief Accounting Officer, appointed interim CFO and interim principal financial officer effective August 21, 2026
Company says the leave is not due to financial statement or accounting issues and that it is not a focus of the government investigation
Company has engaged outside counsel, is conducting its own investigation and is cooperating with the government
On August 21, 2026, Skye Bioscience entered a Securities Purchase Agreement with an affiliate of Redmile Group under which the company can sell up to $22,000,000 of its common stock over three years, subject to conditions. The deal is tied to the proposed acquisition of Redx Pharma Limited and a related private placement, and the share sales would add to the number of shares outstanding.
Equity line of up to $22,000,000, reduced by any amount the funded PIPE exceeds $103,000,000; no shares are sold if the funded PIPE amount reaches $125,000,000 or more
Monthly sales capped at $2,000,000 of shares, priced at the lesser of the PIPE price and market price, with a floor 10% below the PIPE price
Warrant issued at closing to purchase shares equal to $5,000,000 divided by the PIPE price, exercisable from January 1, 2027 to January 1, 2030
Share issuances capped at 19.99% of outstanding common stock absent stockholder approval; company must file a resale registration statement within 10 business days of the closing date
At its recessed annual meeting on August 21, 2026, New Concept Energy stockholders approved issuing 2,000,000 new common shares to Realty Advisors, Inc. (RAI) for $1.00 per share in cash, or $2,000,000 in total. The issuance will proceed only after the NYSE American approves the additional listing application, and the filing states that it will cause a change in control, with RAI owning about 33.65% of outstanding shares afterward.
Stockholders approved the issuance with 1,872,051 votes for, 128,492 against and 120 abstentions.
RAI will pay $1.00 per share, $2,000,000 in total, from its working capital once the NYSE American approves the listing.
After the issuance RAI would hold 2,400,000 of 7,131,935 outstanding shares, about 33.65%, versus 400,000 shares (7.79%) it holds now.
NAPCO Security Technologies reported fiscal fourth-quarter and full-year 2026 results for the period ended June 30, 2026. Fourth-quarter revenue and net income reached records, while full-year net income slipped 0.9% after a $16 million litigation settlement charge in the third quarter. The board also declared a quarterly dividend of $0.17 per share, an increase of 13.3%.
Q4 net income rose 52.7% to a record $17.8 million; diluted EPS was $0.50, including about $0.09 from net tariff refunds.
Full-year net income fell 0.9% to $43.0 million, while diluted EPS rose 0.8% to $1.20 and non-GAAP diluted EPS was $1.60.
Full-year net revenue rose 11.4% to a record $202.3 million; recurring service revenue rose 13.0% to $97.5 million.
Quarterly dividend increased 13.3% to $0.17 per share, payable October 2, 2026, to holders of record September 11, 2026.
Capricor Therapeutics said the FDA extended the PDUFA target action date for the Deramiocel Biologics License Application from August 22, 2026 to November 22, 2026, after classifying the company's amendment as a major amendment. The amendment adds 24-month open-label extension data from the Phase 3 HOPE-3 study and seeks review for a refined indication focused on upper limb function, which delays the timing of a possible FDA decision on the therapy.
PDUFA target action date moved from August 22, 2026 to November 22, 2026, a three-month extension
FDA classified the submission as a major amendment and accepted it for review through CBER
Amendment includes 24-month open-label extension data from the HOPE-3 study and a request to review a refined indication focused on upper limb function
CEO Linda Marbán said HOPE-3 met its primary endpoint, a statistically significant benefit in upper limb function
Trex Company named Brian J. Taylor to a newly created Senior Vice President and Chief Commercial Officer role, effective August 24, 2026, overseeing sales, marketing, and information technology. Taylor previously served as Vice President Sales, North America at PoolCorp and spent 24 years at Sherwin-Williams, and the filing lists his compensation package, including a $480,000 base salary.
Taylor is effective August 24, 2026, and is the company's first Chief Commercial Officer, a newly created role.
Compensation includes a $480,000 annual base salary, a $100,000 cash signing bonus, and time-based RSUs valued at $450,000 vesting over three years.
Taylor was Vice President Sales, North America at PoolCorp from March 2025 to August 2026, and held sales and marketing roles at Sherwin-Williams for 24 years.
Change-in-control and severance agreements are standard company forms, with a 1.5 times salary-and-incentive lump sum under the change-in-control agreement.
Rocky Mountain Chocolate Factory appointed David Denker, its former Vice President of Franchise Development, as Chief Operating Officer, with the filing stating an effective date of August 14, 2026. He will oversee operations, including Durango manufacturing, franchise operations and franchise development, and the filing sets out his base salary and incentive terms.
Board approved the appointment on August 18, 2026, effective August 14, 2026
Annual base salary of $185,000, with an initial annual cash bonus target of 50% of base salary
Restricted stock unit grant valued at $82,500 at target performance, subject to performance goals and continued service
Responsibilities expanded to include Durango manufacturing and production, franchise operations and franchise development
Expion Energy closed a $9.0 million private placement of 8% convertible debentures, with about $8.2 million in expected net proceeds, and acquired oil and gas assets in Eastern Louisiana for an adjusted cash price of $3,425,000. Kevin Sellers replaced Joseph Hammer as chief executive effective August 24, 2026, and the lead investor is affiliated with Hammer, who remains interim chairman. The financing is convertible into preferred stock and warrants, which could dilute shareholders, and the company is shifting into a new business line.
$9.0 million 8% convertible debentures due August 21, 2029, with net proceeds of about $8.2 million; conversion into Series A-1 preferred requires shareholder approval, with an initial conversion price of $4.25 per share.
Warrants to purchase up to 2,117,219 common shares; investors may buy up to $91.0 million of additional convertible preferred stock, subject to shareholder approval.
Acquired Eastern Louisiana oil and gas assets for an adjusted cash price of $3,425,000; the exploration agreement commits up to $4,000,000 to leasing and calls for a new lateral wellbore by February 15, 2027.
Kevin Sellers named CEO and board member effective August 24, 2026; lead purchaser Five Narrow Lane LP is affiliated with Joseph Hammer, who stepped down as CEO and remains interim chairman.
Erasca announced that the FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma. The designation can allow more frequent FDA interactions and may expedite review, but it does not change approval standards or increase the likelihood of U.S. marketing approval.
FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma, announced August 24, 2026.
Designated programs may gain more frequent FDA interactions and may be eligible for accelerated approval, priority review, or rolling review if criteria are met.
The FDA may later revoke the designation or decide review timing will not be shortened.
The company plans a phase 3 trial in pancreatic cancer and two potentially registration-enabling lung cancer trials.
Kimbell Royalty Partners completed the $221.2 million Drop Down acquisition of mineral and royalty interests from affiliated sellers on August 21, 2026, paying about $75 million in cash and issuing 9,500,000 OpCo Common Units and an equal number of Class B Units. On August 24, 2026, it raised its guidance, with midpoint Q3 and Q4 2026 production now 10% and 15% above the midpoint of prior 2026 guidance. The new units are exchangeable into Common Units and will be covered by a resale registration statement that Kimbell must file within 5 business days of the closing.
Drop Down closed August 21, 2026: about $75 million in cash plus 9,500,000 OpCo Common Units and Class B Units (OpCo units valued at about $146.3 million)
Q3 2026 net production guidance of 26.5 to 29.5 Mboe/d; Q4 2026 guidance of 27.7 to 30.7 Mboe/d
Midpoint of guidance is 10% higher for Q3 and 15% higher for Q4 than prior 2026 guidance; cash G&A per Boe guidance lowered
Shelf registration statement to be filed within 5 business days of closing and made effective within 120 days
Datacentrex said it has secured colocation space for more than 500 additional ElphaPex DG2 Scrypt ASIC miners, which it expects to energize within 30 days. The company says the miners were prepaid in 2025, so no additional capital will be spent on the units, and the filing reports no financial results for the period. For shareholders, the expansion would raise deployed hashrate by about 21%, but the filing gives no revenue, profit or cost figures to judge its financial effect.
More than 500 ElphaPex DG2 miners; delivery and energization expected within 30 days of August 24, 2026
Miners were prepaid in full in 2025; company says no additional capital will be deployed and cash is unaffected
Expected to add about 9.0 TH/s, raising deployed hashrate to about 52 TH/s, an increase of about 21%
Current fleet: 3,085 Scrypt ASIC miners, about 43.2 TH/s and 12.5 MW across four US colocation facilities
Azenta's President and CEO John Marotta resigned from the company and its Board effective August 22, 2026, and the Board named director Dr. Martin Madaus as interim President and CEO. The company reaffirmed its fourth quarter fiscal 2026 total revenue guidance but expects a one-time approximately $3 million consulting expense to affect fourth quarter adjusted EBITDA, and a search for a permanent CEO is underway.
John P. Marotta resigned as President, CEO and director effective August 22, 2026; the company says the resignation was not due to any disagreement on operations, policies or practices.
Dr. Martin D. Madaus, a Board member since January 2024, was elected interim President and CEO effective August 22, 2026, and will step down from the Nominating and Governance Committee chair role.
Fourth quarter fiscal 2026 total revenue guidance, issued August 4, 2026, was reaffirmed; adjusted EBITDA will be affected by a one-time approximately $3 million consulting expense.
The Board reduced its size from nine to eight members, and the company has retained Heidrick & Struggles to search for a permanent CEO.
RUM Group's affiliate signed a six-year commercial agreement with an unaffiliated U.S. cloud customer to supply GPU services at the company's Maysville, GA site, which is still under development, with a total order value of approximately $13.7 billion. In connection with the deal, the company entered a binding term sheet to issue the customer a warrant for up to 50,808,408 Class A shares at $0.01 per share, which creates potential dilution for existing shareholders, and the company disclosed that it does not currently have financing for the required spending.
Customer will buy GPU services in three tranches with a total order value of approximately $13.7 billion; the third tranche requires the customer's approval of the proposed delivery date.
Warrant covers up to 50,808,408 Class A shares at $0.01 per share; the initial 50% vests in three 16.67% tranches tied to the customer's purchases.
The remaining 50% of warrant shares can vest in five 10% tranches only if the customer signs one or more expansion agreements.
The company has no current financing for the project, and its obligations under the commercial agreement are not subject to any financing condition.
Martin Marietta completed its combination with Lhoist North America (LNA) on August 21, 2026, and issued Consideration Shares to LNA Holding as part of the deal. Under a new shareholders agreement, LNA Holding gets the right to designate one director, the board expands from ten to eleven seats, and Philipp Niemann was appointed to the new seat. The company says it will provide updated full-year 2026 revenue and Adjusted EBITDA guidance with its third-quarter results.
Combination with Lhoist North America completed on August 21, 2026; announced in a press release dated August 24, 2026
LNA Holding's stake is subject to lock-up: 50% released at the 12-month anniversary of closing and 50% at the 24-month anniversary
Philipp Niemann, CEO of Lhoist S.A., appointed to the board effective August 21, 2026 and will serve on the Finance Committee
Standstill restricts FGI and LNA Holding from acquiring shares above 12,783,660 shares (18% of common stock as of closing)
ANI Pharmaceuticals appointed Henry Gosebruch, former AbbVie strategy chief and former Neumora CEO, as a director effective August 19, 2026. Director Muthusamy Shanmugam resigned from the board on August 23, 2026, but remains an executive as Head of R&D and Chief Operating Officer of New Jersey Operations. The filing describes Gosebruch's role as supporting business development and capital allocation, which is relevant to shareholders as the company pursues its Rare Disease transformation.
Henry Gosebruch, 53, appointed to the Board with a term expiring at the 2027 annual meeting
Initial restricted stock award with a grant date fair value of $525,000, vesting in three equal annual installments
Samy Shanmugam resigned as a director effective immediately on August 23, 2026, and stays in his executive role
Precision BioSciences said it dosed the first patient in its Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD, a gene-editing treatment for Duchenne muscular dystrophy, at Arkansas Children's Hospital. The company said it expects to report initial safety data by year-end 2026. The filing reports no financial results, so it does not show a change in the company's financial position.
First patient dosed in August 2026 at Arkansas Children's Hospital
Study enrolls ambulatory DMD patients aged 2 to 7 with exon 45-55 mutations, which the company says cover up to 60% of boys with DMD
Company expects initial safety data by year-end 2026
Trial is registered as NCT07429240 on clinicaltrials.gov
Extra Space Storage's board selected President W. Noah Springer to succeed Joseph D. Margolis as chief executive, effective January 1, 2027, when Margolis retires after serving through December 31, 2026. Margolis will then serve as an advisor to the board, and Springer will join the board on the same date.
Springer, 47, has been President since January 2026 and joined the company in 2006.
Springer's annual base salary will be $850,000, with continued eligibility for bonus and equity awards.
Margolis has served as CEO since 2017 and will remain a director until December 31, 2026.
The filing reports no financial results; the change is a leadership succession announced August 24, 2026.
Comstock Inc. closed the sale of its mineral, mining, processing and mining-district real estate entities to Mackay Precious Metals Inc., a subsidiary of Mackay Gold & Silver Corp. The company says the transaction, valued at more than $45 million, reduces ongoing costs and enhances balance sheet liquidity, and it expects a gain of about $10 million to $12 million.
Comstock has received $20 million in cash and 2 million Mackay Gold & Silver common shares, currently valued at about $4.5 million
Expected gain of about $10 million to $12 million, with no cash taxes expected on the gain
A secured second-tranche payment of $7 million is due within 18 months
Estimated annual operational savings of $1.5 million; Comstock retains a 1.5% NSR royalty and a $10 million contingent payment tied to a mine construction decision or a change-of-control deal of at least $500 million within seven years
A federal court in California ruled in several related cases involving Sable's Santa Ynez Pipeline System. The court found Sable violated the 2020 consent decree by restarting operations without state authorization, imposed a $1.449 million penalty, and declined to order a shutdown because the federal pipeline regulator PHMSA had approved the Restart Plan. The court also denied California's bid for a preliminary injunction against the federal Defense Production Act order, and California filed a notice of appeal on August 20, 2026.
Court found Sable violated the Consent Decree by restarting the onshore pipeline without OSFM authorization, but declined to order a shutdown.
Court imposed a $1.449 million penalty on the Company.
Court denied California's motion for a preliminary injunction against the DPA Order; California filed notice of appeal on August 20, 2026.
In a separate case, the court declared the DPA Order bars California Department of Parks and Recreation from suing to stop Sable's onshore operations; defendant filed notice of appeal on August 21, 2026.
Ecovyst appointed Laurie Bergman as Vice President, Chief Financial Officer and Treasurer effective August 24, 2026, replacing Michael Feehan, who had held the role since August 2021. Feehan will stay on through September 30, 2026 to transition his duties, and his separation is treated as a termination without cause with severance under his existing agreement. The change in the company's top finance role, along with the disclosed pay terms, is the key shareholder-relevant event in this filing, which contains no financial results.
Laurie Bergman, 49, becomes CFO and Treasurer effective August 24, 2026, succeeding Michael Feehan, who served in the role since August 2021.
Feehan continues as an employee of Ecovyst Catalyst Technologies LLC through September 30, 2026; his separation is considered a termination without cause.
Bergman's offer letter provides a $470,000 base salary, a target bonus of 70% of base salary, a $250,000 one-time sign-on payment and a $450,000 time-based RSU award vesting on the third anniversary of grant.
The Transition Agreement and Offer Letter will be filed as exhibits to the Form 10-Q for the quarter ending September 30, 2026.
On August 21, 2026, a Delaware federal jury returned a verdict in patent infringement action brought by Beckman Coulter against Cytek Biosciences. The jury found noninfringement and invalidity on three of four asserted claims, but found infringement under the doctrine of equivalents on one claim and awarded $20 million in lost profits and $36.11 million in royalties. The company plans post-verdict motions and may appeal, and says the verdict does not require changes to its current products or operations.
Jury found noninfringement and invalidity on three of the four asserted patent claims.
On the remaining claim, jury found no literal infringement but found infringement under the doctrine of equivalents.
Past damages awarded: $20 million in lost profits and $36.11 million in royalties.
Company intends to pursue post-verdict motions and may appeal to the Federal Circuit; it says its products remain available.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.